The company shifted focus to left-heart access products with revenue up 156% year-over-year in Q3 2024, achieving gross margin improvement to 5% from negative 44%. The company no longer provides financial guidance due to its plan to realign resources to support the left-heart access distribution business and exit from electrophysiology mapping and ablation businesses. Trading on OTC markets as of 2026, Acutus is in transition with limited liquidity and financial headroom.
Cyborg Score Rationale
Acutus has pivoted away from its original high-potential cardiac mapping technology to become a distributor of left-heart access products. The company now trades OTC with minimal stock price and provides no forward guidance. While the Q3 2024 revenue surge reflects early traction in the new model, execution risk is high given dependence on partner relationships and a significantly reduced cash position.
Top Insights
(2024) Exited core electrophysiology mapping and ablation businesses to focus exclusively on left-heart access product distribution
(Q3 2024) Achieved 156% YoY revenue growth and improved gross margins to 5% from negative 44% through higher production volumes and reduced overhead
(2024) Stock delisted from NASDAQ to OTC markets; stock price severely depressed at $0.0002 as of January 2026
(May 2026) Q4 2025 earnings reported; company provides no financial guidance and continues to wind down legacy operations
Named Competitors
Medtronic Left-Heart Access — Transseptal crossing devices and left-heart access systems (exclusive distributor of Acutus manufacturing)
Baylis Medical — Transseptal crossing and left-heart access device manufacturer
Merit Medical Systems — Interventional cardiovascular devices including transseptal access products
Edwards Lifesciences — Structural heart and cardiac access devices for interventional procedures